Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

137.29USD
22 Nov 2017
Change (% chg)

$-1.05 (-0.76%)
Prev Close
$138.34
Open
$138.30
Day's High
$138.38
Day's Low
$136.60
Volume
3,917,467
Avg. Vol
5,267,007
52-wk High
$144.35
52-wk Low
$109.32

Chart for

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.81
Market Cap(Mil.): $368,832.31
Shares Outstanding(Mil.): 2,686.52
Dividend: 0.84
Yield (%): 2.45

Financials

  Industry Sector
P/E (TTM): -- 31.56 15.47
EPS (TTM): -- -- --
ROI: -- 15.17 11.81
ROE: -- 16.58 15.76

Johnson & Johnson drug succeeds in newly diagnosed multiple myeloma patients: study

Johnson & Johnson's blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday.

Nov 21 2017

UPDATE 2-J&J drug succeeds in newly diagnosed multiple myeloma patients-study

Nov 21 Johnson & Johnson's blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday.

Nov 21 2017

J&J multiple myeloma drug succeeds in first-line combination study

Nov 21 Johnson & Johnson's blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with the standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday.

Nov 21 2017

Johnson & Johnson hit with $247 million verdict in hip implant trial

NEW YORK A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay $247 million to six patients who said they were injured by defective Pinnacle hip implants.

Nov 16 2017

Johnson & Johnson wins California lawsuit claiming asbestos in talc caused cancer

A California jury on Thursday ruled in favor of Johnson & Johnson in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company's talc-based products including J&J's Baby Powder.

Nov 16 2017

UPDATE 3-J&J wins California lawsuit claiming asbestos in talc caused cancer

Nov 16 A California jury on Thursday ruled in favor of Johnson & Johnson in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company's talc-based products including J&J's Baby Powder.

Nov 16 2017

UPDATE 2-Johnson & Johnson hit with $247 mln verdict in hip implant trial

NEW YORK, Nov 16 A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay $247 million to six patients who said they were injured by defective Pinnacle hip implants.

Nov 16 2017

J&J wins Calif. lawsuit claiming asbestos in talc caused cancer

Nov 16 A California jury on Thursday ruled in favor of Johnson & Johnson in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company's talc-based products including J&J's Baby Powder.

Nov 16 2017

Johnson & Johnson hit with $247 mln verdict in hip implant trial

NEW YORK, Nov 16 A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay $247 million to six patients who said they were injured by defective Pinnacle hip implants.

Nov 16 2017

Janssen drops U.S. lawsuit against Samsung Bioepis' Remicade copy

SEOUL A unit of healthcare conglomerate Johnson & Johnson has dropped a lawsuit it filed to block a copy of its rheumatoid arthritis drug Remicade produced by South Korea's Samsung Bioepis Co Ltd from being sold in the United States.

Nov 14 2017

Earnings vs. Estimates